drtarsh

MD FRCP MRCGP ICOS-Certified Cardio-Oncologist @RoyalBrompton/Primary Care Physician/@ProstateUKProfs Clinical Champion. #CardioOnc #JACCCardioOnc/Views my own

[drtarsh @drtarsh]

Who is a cardio-oncologist?
Looking after the hearts of cancer patients before, during and long after cancer treatment.

[JACC Journals @JACCJournals]

In a #JACCCardioOnc study of pts w/ ICI-associated #Myocarditis, inflammatory cell infiltration and tissue-level myocardial inflammation were significantly milder in late- vs early-manifestation myocarditis cases, but cancer-related mortality was higher.

https://t.co/DwufBMcyPs

[drtarsh @drtarsh]

@awechalekar Happy Diwali 🪔

[drtarsh @drtarsh]

@DrSanjayPopat Happy Diwali 🪔

[drtarsh @drtarsh]

@NTrayanova @HopkinsEngineer @JHUBME @HopkinsDSAI @trayanovalab One of my favourite pioneers!

[NataliaTrayanova @NTrayanova]

Opened the #AHA26 Daily News and found myself on page 4, labeled a "pioneer." Very kind, though it makes me sound like I arrived by covered wagon. 😄 Come hear about heart digital twins and AI today, 3:45 pm CT, Room S102A. @HopkinsEngineer @JHUBME @HopkinsDSAI @trayanovalab

[Rohan Khera @rohan_khera]

In @NatureMedicine today, led by super⭐️ @cards_lab member and @TradIMYale resident @SudPerera, is our study on digital readiness for cardiovascular care in the US.

Across ~83,000 US census tracts, we find 19.9M residents in high-need areas with higher digital readiness, but 74.1M in areas needing investment.

Explore: https://t.co/JvFLsJfm4K
Paper: https://t.co/IXYw3PSEmi

Come to Sud’s talk on Saturday! #AHA26

[ESC Council of Cardio-Oncology Chairperson @ESCardioOnco]

Want to know more about #CardioOnc?
Try our #CardioTalk!

📢 Promoted by the ESC Council and #COOL Group members, each episode lasts few minutes and covers a topic from daily practice, built around a practical clinical case!

Start from 1️⃣ 🔗 https://t.co/YvILtCM1qN

[Rohan Khera @rohan_khera]

Looking forward to #AHA26 and catching up with colleagues and friends

The @cards_lab team has lots of new work to share.

If you're in Chicago, come find us

Would love to exchange ideas, hear what others are working on, and explore collaborations.

@YaleIMed @YaleMed @ekoikonomou

[International Cardio-Oncology Society @ICOSociety]

Heading to #AHA26 in Chicago? Have a drink with IC-OS President Dr. Mike Fradley!

📅 Sat, Nov 7 | 5-6 PM
📍 Fatpour McCormick, 2206 S Indiana Ave

Casual happy hour for the #CardioOncology community. Hope to see you there!

[Sanjay Popat @DrSanjayPopat]

On a beautiful crisp autumnal London morning, am reflecting on the major practice-changing and development datasets presented @myESMO #ESMO26, the strong @royalmarsdenNHS & @ICR_London faculty leadership, & above all the global friends & colleagues who are
making a difference

[Oncology Brothers @OncBrothers]

We are all done with #ESMO26! 10+ studies that were on our radar and the updated data around them.

Out in the community settings, it’s tough to keep up with all that is happening here in the world of cancer (and this was just ONE conference). Really appreciate you all sharing the data and importantly your take around this: @OncoAlert @weoncologists @DrChoueiri @StephenVLiu @SuyogCancer @dr_yakupergun @drsarahsam @PTarantinoMD @GIMedOnc @BijoyTelivala @RenoHemonc @nlindenberg @jryckman3 @ErikaHamilton9 @myESMO @LorenzaRimassa 🙏🏽🙏🏽

[Mike Fradley, MD @Dr_Mike_Fradley]

Fantastic session highlighting the role of AI in #cardioonc @ICOSociety

[Journal of Physiology @JPhysiol]

Latest special issue now live! 🎉

'Computational modelling of the cardiovascular system: From cell to circulation' was organised and edited by Professors @NTrayanova and Christian Vergara @polimi

Cover image by Regazzoni et al.📸

📖 Read all articles https://t.co/wUNzC9v0vz

[drtarsh @drtarsh]

A huge step forward in personalised cancer care.Warmest congratulations to Professor Georgina Long and the entire INTerpath-001 team on these exciting phase III results presented at ESMO in Madrid.

How is the vaccine personalised? Scientists compare the patient’s tumour DNA with their normal DNA to identify cancer-specific changes. These inform a bespoke mRNA vaccine encoding up to 34 tumour-specific targets, designed to help T cells recognise and attack that patient’s cancer.
This is what makes these results so compelling: treatment designed around an individual cancer’s molecular signature, translating into meaningful clinical benefit. Eagerly awaiting the cardiac safety data in the full publication in @NEJM in November.
@OncBrothers @HanCardiomd
#ESMO26 #PersonalisedMedicine #CancerVaccines #Melanoma #PrecisionOncology #CardioOncology

[Professor Georgina Long AO (Bluesky @gvlongphdmd) @ProfGLongMIA]

It was a great honour to present the results of the phase 3 INTerpath-001 clinical trial at the #ESMO26 Congress in Madrid.

This international trial included 1137 patients, across 157 sites, whose melanoma had been surgically removed, but who were at very high risk of it returning. The trial showed adding #intismeran autogene, an mRNA based individualised neoantigen therapy, to pembrolizumab reduced the risk of recurrence or death by 42%.

This is the first phase 3 study to show that a treatment built from the unique ‘fingerprint’ of a patient’s own tumour can reduce the risk of recurrence or death from cancer. That fingerprint is read by sequencing the tumour, then a ‘wanted poster’ of the cancer is made as mRNA, showing the immune system exactly what to look for and attack. Having succeeded in melanoma, this proof of concept could mark the beginning of a foundational shift in how we treat cancer.
Read more >https://t.co/quxTAFfntb

A huge thank you to all patients and teams involved.
@myESMO @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @NthSydHealth @ausoftheyear

[drtarsh @drtarsh]

@datsunian @LeivaOrly @UCLAHealth @JHHirschbaum @LizGhandakly @A_SteinMerlob @UCLAHealthJCCC @uclaimchiefs @DOM_UCLA @IntMedAbel @jamil_aboulhosn @Vijayrao7474 @AliZaidiMD @achd_nyc Congratulations Eric

[Eric H Yang, MD @datsunian]

In #ACHD, #Fontan pts are a unique combo of anatomy & pathophysiology that can make cardiotoxicity risk difficult to gauge & manage

In this @UCLAHealth collab led by @JHHirschbaum #GentianLluri we explore the tx & outcomes in a #cardioonc case series

https://t.co/CUS6SLal6o

1/

[International Cardio-Oncology Society @ICOSociety]

IC-OS is honored to be attending the 3rd International Pediatric Cardio-Oncology Conference, hosted by our friends at @SofiasHopeNPO, @CincyChildrens and the Pediatric Cardiomyopathy Registry.

#CardioOncology #CardioOnc #PedicatricCancer #ChildhoodCancer

[Bonnie Ky, MD, MSCE, FACC @DrBonnieKy]

What happens to the 🫀 during cancer therapy?

In this study, proteomic and metabolomic profiling identified novel biomarkers associated with cardiac remodeling and dysfunction in #breastcancer patients receiving cardiotoxic therapies. #CardioOnc

📰https://t.co/IMrjdcSJjM